Biocytogen Pharmaceuticals Receives CNIPA Patent for RenMab Human Antibody Mice Platform
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award...
BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...
Jiangsu Hengrui Pharmaceutials’ SHR-1209 for Hypercholesterolemia Accepted for NMPA Review
China-based Jiangsu Hengrui Pharmaceutials (SHA: 600276) has announced that a market filing for its Category...
Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates
China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in...
Xiamen ITG Group and Fosun Health Collaborate on Big Health Industry Fund and Medical Device Commercialization
China-based Xiamen ITG Group Co., Ltd. (SHA: 600755) and Shanghai Fosun Health Technology (Group) Co.,...
Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product
Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the...
CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890
The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...
Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III...
Boehringer Ingelheim’s Spevigo on Track for Priority Review for GPP Flare Prevention in China
Germany-based Boehringer Ingelheim’s (BI) interleukin-36 receptor (IL-36R)-targeted orphan drug, Spevigo (spesolimab), in subcutaneous injection form,...
Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China
Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has...
Pfizer to Establish Smart Medical Innovation Center in Hangzhou’s Qiantang District
US pharmaceutical giant Pfizer (NSE: PFIZER) has announced a plan to establish a smart medical...
Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide
Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for...
Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform
Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry...
Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics
China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...
Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor
Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit...
Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China
China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE:...
Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...
Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations
Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has...
Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million...
Shanghai Pharmaceuticals’ SPH3127 for Hypertension Gets MNPA Review Acceptance
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...